Edition:
United States

Regeneron Pharmaceuticals Inc (REGN.OQ)

REGN.OQ on NASDAQ Stock Exchange Global Select Market

372.32USD
25 Apr 2017
Change (% chg)

$0.39 (+0.10%)
Prev Close
$371.93
Open
$373.09
Day's High
$376.00
Day's Low
$370.01
Volume
267,280
Avg. Vol
299,361
52-wk High
$452.83
52-wk Low
$325.62

Latest Key Developments (Source: Significant Developments)

Sanofi and Regeneron announce FDA approval of a once-monthly dosing option for Praluent
Tuesday, 25 Apr 2017 08:00am EDT 

April 25 (Reuters) - Sanofi :Sanofi and Regeneron announce FDA approval of a new once-monthly dosing option for Praluent (alirocumab) injection.Sanofi and Regeneron announce FDA approval of a new once-monthly dosing option for Praluent (alirocumab) injection.Monthly dosing schedule now approved in both United States and European Union.  Full Article

Regeneron says FDA approved for praluent injection
Tuesday, 25 Apr 2017 08:00am EDT 

April 25 (Reuters) - Regeneron Pharmaceuticals Inc -:Regeneron and Sanofi announce FDA approval of a new once-monthly dosing option for Praluent (Alirocumab) injection.Regeneron and Sanofi announce FDA approval of a new once-monthly dosing option for Praluent (Alirocumab) injection.  Full Article

Regeneron Pharmaceuticals say CEO Leonard Schleifer's 2016 total compensation was $28.3 mln - SEC filing
Tuesday, 25 Apr 2017 07:41am EDT 

April 25 (Reuters) - Regeneron Pharmaceuticals Inc :Regeneron Pharmaceuticals Inc - CEO Leonard Schleifer's 2016 total compensation was $28.3 million versus $47.5 million - SEC filing.Regeneron Pharmaceuticals Inc - CFO Robert Landry's 2016 total compensation was $5.2 million versus $8.2 million - SEC filing.Regeneron Pharmaceuticals Inc - President George Yancopoulos's total compensation in 2016 was $27.77 million versus $40.30 million.  Full Article

Regeneron announces Evinacumab has received FDA breakthrough therapy designation
Thursday, 6 Apr 2017 07:00am EDT 

Regeneron Pharmaceuticals Inc : Regeneron announces Evinacumab has received FDA breakthrough therapy designation for homozygous familial hypercholesterolemia (HOFH) .Regeneron Pharmaceuticals - Regeneron reported positive interim phase 2 results for Evinacumab in Hofh patients, is currently planning a phase 3 trial.  Full Article

U.S. list price for Sanofi, Regeneron's Dupixent $37,000
Tuesday, 28 Mar 2017 11:47am EDT 

Sanofi : Says U.S. list price of newly approved Dupixent atopic dermatitis drug $37,000 per patient per yearFurther company coverage: [SASY.PA] (Reporting by Ben Hirschler) ((uk.online@reuters.com;)).  Full Article

U.S. FDA says approves new eczema drug Dupixent
Tuesday, 28 Mar 2017 11:47am EDT 

U.S. FDA: FDA approves new eczema drug Dupixent . FDA granted the application for Dupixent priority review and breakthrough therapy designation .FDA granted the approval of Dupixent to Regeneron Pharmaceuticals Inc.  Full Article

Regeneron and Sanofi announce FDA approval of Dupixent
Tuesday, 28 Mar 2017 11:40am EDT 

Sanofi SA : Regeneron and Sanofi announce FDA approval of Dupixent® (Dupilumab), the first targeted biologic therapy for adults with moderate-to-severe atopic dermatitis . Dupixent is expected to be available to patients and providers in U.S. later this week .Regeneron and Sanofi Genzyme, specialty care global business unit of Sanofi, will market Dupixent in United States.  Full Article

UK regulator gives positive opinion on Sanofi/Regeneron's dupilumab product
Tuesday, 14 Mar 2017 04:30am EDT 

Sanofi : Sanofi says UK's Medicines & Healthcare Products Regulatory Agency (MHRA) has granted dupilumab, a product which treats for atopic dermatitis (AD), a positive scientific opinion through the Early Access to Medicines Scheme (EAMS). . The decision means that eligible adults with severe atopic dermatitis can access dupilumab before the drug is granted marketing authorisation in the UK, Sanofi adds in statement .Dupilumab is currently under joint development with Regeneron and Sanofi and its safety and efficacy have not been fully evaluated by any regulatory body. The formal EU regulatory application for dupilumab is currently under review by the European Medicines Agency (EMA)..  Full Article

Regeneron and Sanofi to present new phase 3 praluent (alirocumab) injection clinical trial analyses at ACC.17 Scientific Sessions
Tuesday, 7 Mar 2017 08:00am EST 

Regeneron Pharmaceuticals Inc : Regeneron and Sanofi to present new phase 3 praluent (alirocumab) injection clinical trial analyses at ACC.17 Scientific Sessions .Regeneron Pharmaceuticals Inc says effect of praluent on cardiovascular (CV) morbidity and mortality has not yet been determined.  Full Article

Adverum says Regeneron Pharma elects to extend research term of deal
Wednesday, 1 Mar 2017 04:59pm EST 

Adverum Biotechnologies Inc : Adverum Biotechnologies-on Feb 23, Regeneron Pharma notified Adverum Biotechnologies of election to extend research term of collaboration, licensing deal .Adverum Biotechnologies - Regeneron Pharma elected to extend research term of deal for additional three years, through May 1, 2020.  Full Article

More From Around the Web

BRIEF-Regeneron says FDA approved for praluent injection

* Regeneron and Sanofi announce FDA approval of a new once-monthly dosing option for Praluent (Alirocumab) injection